Drug-conjugate
Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate
... Mucin 1 (MUC1) is a heterodimeric protein that is aberrantly overexpressed on the surface of diverse human carcinomas and is an attractive target for the development of mAb-based therapeutics. However, attempts at ...
12
RECENT ADVANCEMENT OF LIPID DRUG CONJUGATE AS NANOPARTICULATE DRUG DELIVERY SYSTEM
... Lipid Drug Conjugates. To achieve and maintain a lipid drug conjugate upon administration, the lipid nanoparticle’s melting point must exceed body temperature (37 ...
6
Tumor stroma–targeted antibody drug conjugate triggers localized anticancer drug release
... antibody-drug conjugate (ADC) targeting tumor endothelial marker 8 (TEM8, also known as ANTXR1), a highly conserved transmembrane receptor broadly overexpressed on cancer-associated fibroblasts, ...
18
Trastuzumab-DM1: A Clinical Update of the Novel Antibody-Drug Conjugate for HER2-Overexpressing Breast Cancer
... T-DM1 is the first antibody-drug conjugate with a nonreducible thioether linker in clinical trials. Phase I and II clinical trials of T-DM1 as a single agent and in combination with paclitaxel, docetaxel ...
7
A REVIEW ON POLYMER DRUG CONJUGATE – WHAT, WHY AND HOW?
... polymer-drug conjugate is an effective and fast growing technique for improved use of drugs for therapeutic ...as drug delivery systems that exhibit their therapeutic activities by means of releasing ...
11
Synthesis and properties of a biodegradable polymer drug conjugate: Methotrexate poly(glycerol adipate)
... anticancer drug, MTX, to a PGA backbone, the first polymer-anticancer drug conjugate reported with this ...polymer-drug conjugate linker over 30 days and enzymatic ...
36
A review on current nanomaterials and their drug conjugate for targeted breast cancer treatment
... targeted drug delivery ...potential drug nanocarriers with the ability of targeting, imaging and ...their drug conjugates, for breast cancer ...
12
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
... the drug development process of novel therapeutic agents, it is becoming more and more important to concurrently develop companion diagnos- tics [14 – ...antibody-drug conjugate success using the ...
10
Antibody drug conjugate targeting CD46 eliminates multiple myeloma cells
... ADC generation and characterization. MMAF was conjugated to anti-CD46 IgG1 via an mcvcpab linker (29). To create the mcvcpab linker, N-ε-maleimidocaproyloxysuccinimide ester (Pierce) was dis- solved in anhydrous ...
15
Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma
... brain-targeted drug delivery following structural design and phage display ...brain-targeted drug delivery ...brain-targeted drug delivery through LRP-1-mediated transcytosis ...
7
A Nanosystem of Amphiphilic Oligopeptide-Drug Conjugate Actualizing Both αvβ3 Targeting and Reduction-Triggered Release for Maytansinoid
... Here, we design and construct a series of novel peptide-linker-drug conjugates. The maytansinoid DM1 (DM1), a microtubule inhibitor similar to vinca alkaloids [30, 31] was selected as the powerful cytotoxic agent, ...
13
A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors
... It has been previously reported that a mouse mAb, AD5-10, specifically binds to the extracellular domain of human DR5 and induces apoptosis and autophagic cell death in various tumor cell lines and the xenografts of ...
12
A comparative study on the physicochemical properties of polymer and albumin based paclitaxel
... polymer–drug conjugate (GPDC) with paclitaxel (PTXL) as the divalent agent to bridge between the degradable polylactide (PLA)-based backbone and hydrophilic poly(ethylene glycol) (PEG) side chains [46] were ...
8
<p>Ciprofloxacin Functionalized Biogenic Gold Nanoflowers as Nanoantibiotics Against Pathogenic Bacterial Strains</p>
... resultant drug – nano fl ower conjugate was characterized by UV – visible spectroscopy and Fourier transform infrared spectroscopy ...the drug release statistically. The prepared nano fl ower – ...
12
Improving aqueous solubility and antitumor effects by nanosized gambogic acid-mPEG<sub>2000</sub> micelles
... nanosized drug delivery system with the aims of increasing the aqueous solubility, improving the therapeutic efficacy, and reduc- ing the toxicity of gambogic acid to normal ...polymer-drug conjugate ...
13
Membrane active polymer anticancer conjugates
... that tumour targeting of HPMA copolymers via the EPR effect was also independent of molecular weight (4.5 - 800 kDa) (Seymour et al, 1995 and Noguchi et al, 1998). In these studies, radioactivity (’^^I-labelling) was ...
263
Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures
... DLL3 immunohistochemical evaluation will be mandatory for the decision about an application of the DLL3-targeted antibody-drug conjugate in patients with SCLC. The EMA, upon release of the drug, ...
9
Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma
... anti-CD30 drug conjugate, brentuximab vedotin, and classical lymphoma salvage regimen DHAP (cisplatin, high-dose cytarabine and dexamethasone) was ...antibody-drug conjugate brentuximab ...
5
DESIGN, CHARACTERIZATION AND COMPARATIVE EVALUATION OF FOLATE MEDIATED TARGETING OF THERAPEUTICS
... The objective of this study was to utilize the folate-receptor overexpression in cancer cells and inflammatory macrophages for enhanced and site-specific delivery of anti-cancer and anti-rheumatic drugs to their ...
7
A carboxymethyl dextran-based polymeric conjugate as the antigen carrier for cancer immunotherapy
... The conjugate was labeled with ...purified conjugate was stored at − 20 °C, prior to ...the conjugate, a TC-1 flank tumor model was prepared by the subcutaneous inoculation of a cell suspension (1 × ...
7